#Media center os 2016 full
#Media center os 2016 trial

Lynparza (olaparib) is an innovative, first-in-class oral poly ADP-ribose polymerase (PARP) inhibitor that may exploit tumour DNA damage response (DDR) pathway deficiencies to preferentially kill cancer cells. AstraZeneca is committed to the continued development of our R&D portfolio for ovarian cancer, with a focus on improved care for all patients, including the development of targeted therapies for patients with specific gene mutations such as BRCA. 3 The risk of developing ovarian cancer is increased in women with specific inherited genetic abnormalities, including BRCA mutations. Worldwide, ovarian cancer is the 7 th most commonly diagnosed cancer 2 and the 8 th most common cause of cancer death in women.

#Media center os 2016 trial

The trial, conducted in collaboration with the European Network for Gynaecological Oncological Trial Groups (ENGOT) and Groupe dвЂ™Investigateurs National pour lвЂ™Etude des Cancers de lвЂ™Ovaire et du sein (GINECO), randomised 295 patients with documented germline BRCA1 or BRCA2 mutations who had received at least 2 prior lines of platinum-based chemotherapy. Patients were randomised to receive either Lynparza tablets (300mg twice daily) or placebo until disease progression.

Those few patients who were enrolled based on a tumour test were also found to have a germline BRCA mutation. In SOLO-2, patients with either germline or somatic BRCAm status were eligible for enrolment, although due to the lack of widespread availability of tumour BRCA testing, most patients were enrolled on blood-based germline testing.

SOLO-2 was a Phase III, multicentre trial designed to determine the efficacy of Lynparza tablets as a maintenance monotherapy compared with placebo, in patients with platinum-sensitive relapsed or recurrent BRCA-mutated (BRCAm) ovarian cancer. TodayвЂ™s positive results follow the Fast Track Designation for Lynparza by the US FDA earlier this year, in patients with a BRCA mutation who have platinum-sensitive, relapsed ovarian cancer.

#Media center os 2016 full

Full results of SOLO-2 will be presented at a forthcoming medical meeting. Initial findings demonstrate that safety profile with Lynparza tablets was consistent with previous studies. We remain committed to investigating the full potential of Lynparza, both as monotherapy and in combinations, and to identifying all patients who may benefit from this important medicine.вЂќ We will work with regulatory authorities to make Lynparza tablets available as quickly as possible to patients with ovarian cancer. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: вЂњWe are pleased with the robust improvement in progression-free survival demonstrated by Lynparza in the SOLO-2 trial. Importantly, the median PFS in the Lynparza arm of SOLO-2 substantially exceeded that observed in the Phase II maintenance study in patients with platinum-sensitive relapsed ovarian cancer (Study 19). Results from the trial demonstrate a clinically-meaningful and statistically-significant improvement of progression-free survival (PFS) among patients treated with Lynparza compared to placebo and provide additional evidence to support the potential use of Lynparza in this patient population. Initial findings show safety profile with Lynparza tablets was consistent withДЄstraZeneca today announced positive results from the Phase III SOLO-2 trial designed to determine the efficacy of Lynparza (olaparib) tablets (300mg twice daily) as a monotherapy for the maintenance treatment of platinum-sensitive relapsed, BRCA-mutated ovarian cancer. Trial studied Lynparza as maintenance treatment for women with BRCA-mutated metastatic ovarian cancer

Partnerships, alliances and recognition.